Acquisition of resistance to androgen deprivation therapy in salivary duct carcinoma: A case report

Koichiro Wasano, Kohei Sakurai, Taiji Kawasaki, Kimihide Kusafuka, Masao Kasahara, Naoki Kondo, Ken Ichi Inada, Kaoru Ogawa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Salivary duct carcinoma is a relatively rare salivary cancer, and most cases are androgen receptor -positive. Salivary duct carcinoma growth is suggested to be androgen dependent, which can reportedly be controlled by androgen deprivation therapy. However, the effectiveness and underlying molecular mechanisms of androgen deprivation therapy for salivary duct carcinoma remain unknown. We report a salivary duct carcinoma case (65-year-old man) arising from the parotid gland with metastasis to the neck lymph nodes and lungs. Androgen deprivation therapy was performed according to the same protocol for prostate cancer treatment. Expression levels of androgen receptor and FOXA1 (forkhead box A1) were immunohistochemically analyzed before and after androgen deprivation therapy. Although the tumor volume was partially diminished during the first 3 months, acquired resistance to androgen deprivation therapy occurred. FOXA1 was not detected in parotid gland after androgen deprivation therapy, whereas androgen receptor expression was positive. FOXA1 expression might be related to acquired androgen deprivation therapy resistance in salivary duct carcinoma.

Original languageEnglish
JournalRare Tumors
Volume10
DOIs
Publication statusPublished - 01-09-2018

Fingerprint

Salivary Ducts
Androgens
Carcinoma
Androgen Receptors
Parotid Gland
Therapeutics
Antineoplastic Protocols
Tumor Burden
Prostatic Neoplasms
Neck
Lymph Nodes
Neoplasm Metastasis
Lung

All Science Journal Classification (ASJC) codes

  • Histology
  • Oncology

Cite this

Wasano, Koichiro ; Sakurai, Kohei ; Kawasaki, Taiji ; Kusafuka, Kimihide ; Kasahara, Masao ; Kondo, Naoki ; Inada, Ken Ichi ; Ogawa, Kaoru. / Acquisition of resistance to androgen deprivation therapy in salivary duct carcinoma : A case report. In: Rare Tumors. 2018 ; Vol. 10.
@article{a0a13fe449bd457680ffa7d559045b46,
title = "Acquisition of resistance to androgen deprivation therapy in salivary duct carcinoma: A case report",
abstract = "Salivary duct carcinoma is a relatively rare salivary cancer, and most cases are androgen receptor -positive. Salivary duct carcinoma growth is suggested to be androgen dependent, which can reportedly be controlled by androgen deprivation therapy. However, the effectiveness and underlying molecular mechanisms of androgen deprivation therapy for salivary duct carcinoma remain unknown. We report a salivary duct carcinoma case (65-year-old man) arising from the parotid gland with metastasis to the neck lymph nodes and lungs. Androgen deprivation therapy was performed according to the same protocol for prostate cancer treatment. Expression levels of androgen receptor and FOXA1 (forkhead box A1) were immunohistochemically analyzed before and after androgen deprivation therapy. Although the tumor volume was partially diminished during the first 3 months, acquired resistance to androgen deprivation therapy occurred. FOXA1 was not detected in parotid gland after androgen deprivation therapy, whereas androgen receptor expression was positive. FOXA1 expression might be related to acquired androgen deprivation therapy resistance in salivary duct carcinoma.",
author = "Koichiro Wasano and Kohei Sakurai and Taiji Kawasaki and Kimihide Kusafuka and Masao Kasahara and Naoki Kondo and Inada, {Ken Ichi} and Kaoru Ogawa",
year = "2018",
month = "9",
day = "1",
doi = "10.1177/2036361318798867",
language = "English",
volume = "10",
journal = "Rare Tumors",
issn = "2036-3605",
publisher = "PagePress",

}

Acquisition of resistance to androgen deprivation therapy in salivary duct carcinoma : A case report. / Wasano, Koichiro; Sakurai, Kohei; Kawasaki, Taiji; Kusafuka, Kimihide; Kasahara, Masao; Kondo, Naoki; Inada, Ken Ichi; Ogawa, Kaoru.

In: Rare Tumors, Vol. 10, 01.09.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Acquisition of resistance to androgen deprivation therapy in salivary duct carcinoma

T2 - A case report

AU - Wasano, Koichiro

AU - Sakurai, Kohei

AU - Kawasaki, Taiji

AU - Kusafuka, Kimihide

AU - Kasahara, Masao

AU - Kondo, Naoki

AU - Inada, Ken Ichi

AU - Ogawa, Kaoru

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Salivary duct carcinoma is a relatively rare salivary cancer, and most cases are androgen receptor -positive. Salivary duct carcinoma growth is suggested to be androgen dependent, which can reportedly be controlled by androgen deprivation therapy. However, the effectiveness and underlying molecular mechanisms of androgen deprivation therapy for salivary duct carcinoma remain unknown. We report a salivary duct carcinoma case (65-year-old man) arising from the parotid gland with metastasis to the neck lymph nodes and lungs. Androgen deprivation therapy was performed according to the same protocol for prostate cancer treatment. Expression levels of androgen receptor and FOXA1 (forkhead box A1) were immunohistochemically analyzed before and after androgen deprivation therapy. Although the tumor volume was partially diminished during the first 3 months, acquired resistance to androgen deprivation therapy occurred. FOXA1 was not detected in parotid gland after androgen deprivation therapy, whereas androgen receptor expression was positive. FOXA1 expression might be related to acquired androgen deprivation therapy resistance in salivary duct carcinoma.

AB - Salivary duct carcinoma is a relatively rare salivary cancer, and most cases are androgen receptor -positive. Salivary duct carcinoma growth is suggested to be androgen dependent, which can reportedly be controlled by androgen deprivation therapy. However, the effectiveness and underlying molecular mechanisms of androgen deprivation therapy for salivary duct carcinoma remain unknown. We report a salivary duct carcinoma case (65-year-old man) arising from the parotid gland with metastasis to the neck lymph nodes and lungs. Androgen deprivation therapy was performed according to the same protocol for prostate cancer treatment. Expression levels of androgen receptor and FOXA1 (forkhead box A1) were immunohistochemically analyzed before and after androgen deprivation therapy. Although the tumor volume was partially diminished during the first 3 months, acquired resistance to androgen deprivation therapy occurred. FOXA1 was not detected in parotid gland after androgen deprivation therapy, whereas androgen receptor expression was positive. FOXA1 expression might be related to acquired androgen deprivation therapy resistance in salivary duct carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=85054662755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054662755&partnerID=8YFLogxK

U2 - 10.1177/2036361318798867

DO - 10.1177/2036361318798867

M3 - Article

AN - SCOPUS:85054662755

VL - 10

JO - Rare Tumors

JF - Rare Tumors

SN - 2036-3605

ER -